Early drug attack on silent blood cancer
NCT ID NCT02518555
Summary
This study is testing whether starting a cancer drug called ibrutinib early, before symptoms appear, can better control high-risk forms of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It involves 42 patients who have these cancers with specific high-risk genetic features but no current symptoms. The trial also checks if giving common vaccines alongside the drug helps the immune system respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.